M13 Phage Gene Therapy Platform for Blood-Brain Barrier Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies lack efficient and targeted delivery systems for therapeutic agents to specific tissues, particularly across the blood-brain barrier, and there is a need for improved nanocarriers that can enhance ion transport and material access in medical applications.
Innovation Solution
M13 bacteriophage particles are engineered to vary in length from 25 nm to 2500 nm, with a chlorotoxin motif for blood-brain-barrier penetration and homing to glioblastoma cells, and used to create transgene cassettes for targeted gene delivery, incorporating imaging agents like indocyanine green dye for enhanced localization and therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional delivery systems are used, then delivery to general tissues is achieved, but targeted delivery across the blood-brain barrier to specific tissues is insufficient
Solution Approach 1:
The patent applies local quality by engineering M13 phage particles with specific modifications: displaying chlorotoxin peptides on the phage surface for targeted binding to glioblastoma cells, and incorporating imaging agents like indocyanine green at specific locations. This localized functionalization enables the phage to specifically target and penetrate the blood-brain barrier while maintaining general phage delivery capabilities, thus resolving the contradiction between targeted delivery efficiency and adaptability.
2Quantity of substance
If phage particle length is increased, then cargo capacity is improved, but tissue trafficking and localization specificity are reduced
Solution Approach 1:
The patent applies parameter changes by systematically varying the length of M13 phage particles (ranging from ultrashort to full-length) and measuring their effects on both cargo capacity and tissue trafficking. The study identifies optimal phage lengths that balance cargo capacity with localization specificity, demonstrating that controlled parameter adjustment can resolve the contradiction between quantity of cargo and precision of delivery.
3Reliability
If a multifunctional nanoplatform is created, then therapeutic efficacy is enhanced, but device complexity increases
Solution Approach 1:
The patent applies universality by creating a multifunctional M13 phage nanoplatform that simultaneously performs multiple functions: (1) delivers therapeutic cargo to target cells, (2) penetrates the blood-brain barrier via chlorotoxin display, (3) enables imaging through incorporated imaging agents, and (4) provides targeted transduction of cancer cells. By integrating these diverse functions into a single phage-based system, the patent enhances therapeutic efficacy while managing complexity through the use of a unified nanoplatform architecture.
Data Source
AI summary
An engineered phage-derived particle (PDP) for expressing a transgene in a target cell transduced with a bacteriophage, the PDP includes (i) less than about 500 bp of DNA from the bacteriophage genome, (ii) an ITR-flanked therapeutic gene up to 20 kb, (iii) an endosomal escape sequence, (iv) a nuclear localization sequence, and (v) a cell-specific targeting moiety. The PDP may escape lysosomal degradation, traffic across the nuclear envelope and expressed a therapeutic gene in a mammalian cell.